US Corporations Enjoy Tax Windfall Amid Global Tax Evasion Effor

US corporations have reportedly avoided at least $40 billion in income taxes since early 2025 after the US withdrew from a global minimum tax effort, benefiting multinationals shifting profits to low-tax jurisdictions. For Amgen (AMGN), the article is mostly a valuation and fundamentals update: GF Value of $353.15 versus a $336.19 current price implies 4.8% undervaluation, with a GF Score of 92/100 and a TTM P/E of 23.4x versus a 5-year median of 23.06x. Insider activity was light, with no buying and about $0.4 million of selling over the past three months.

Analysis

The important second-order effect is not the tax savings itself, but the widening dispersion between firms that can credibly domicile intangibles offshore and those that cannot. For a company like AMGN, the incremental benefit is less about a one-time EPS pop and more about a longer-duration uplift to free cash flow conversion, which can quietly support higher buyback capacity and reduce the market’s discount for pipeline execution risk over the next 6-18 months.

Healthcare and biotech should screen as structural beneficiaries because their value creation is concentrated in IP, not physical plant, making profit shifting easier than for industrials or retailers. That means the market may underappreciate a relative multiple expansion for large-cap pharma/biotech versus domestically oriented healthcare names, especially if investors start treating tax rate variability as a durable feature rather than a temporary policy gap. The flip side is that any company already trading at a premium for quality, like AMGN, may see less incremental rerating than peers with similar fundamentals but more exposed effective-tax-rate upside.

The main risk is policy reversal: this is a legislative and diplomatic overhang, not a permanent economic moat. If Treasury or Congress moves to claw back lost revenue, the first names to underperform will be the high-cash-generation multinationals with the cleanest offshore earnings profiles, and that unwind could happen fast once the budget debate turns concrete, likely over the next 1-3 quarters. A second-order concern is reputational: boards may become more conservative about aggressive tax optimization if media scrutiny intensifies, capping the durability of the benefit.

Key Decisions for Investors

• Go long AMGN vs. a healthcare basket with weaker FCF conversion for a 3-6 month horizon; the trade expresses relative tax-efficiency benefit while limiting beta to the sector.
• Prefer long large-cap biotech/pharma with meaningful overseas IP structures over domestically focused healthcare providers; use pullbacks to add, targeting 5-8% relative outperformance over 2 quarters.
• Avoid paying up for ultra-tax-sensitive multinationals until policy risk clears; consider a short basket of high-foreign-margin mega-cap tech/pharma against a long quality defensive basket as a policy-risk hedge.
• If AMGN rallies toward the upper end of implied value without a policy response, use call spreads rather than outright stock to capture modest upside while limiting downside if legislation closes the loophole.
• Set a 1-3 month catalyst watch on US fiscal headlines; if Congress signals a revenue-recapture package, reduce exposure to offshore-IP beneficiaries immediately, as the reversal risk is abrupt rather than gradual.